Shall we dance? Extending tango's results to clinical practice

Simona Di Giambenedetto, Alberto Borghetti, Arturo Ciccullo, Gianmaria Baldin, Stefano Rusconi, Amedeo Capetti, Gaetana Sterrantino, William Gennari, Cristina Mussini, Vanni Borghi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

After previous evidence from the ASPIRE trial [1], results from TANGO study [2] definitively proved the efficacy of lamivudine (3TC) plus dolutegravir (DTG) as a maintenance strategy. As trials’ populations often differ from real-practice settings, we aimed to assess whether these results are reproducible in an unselected HIV-population. An observational longitudinal multicenter research study was conducted. HIV-positive patients with viral suppression (at least one HIV-RNA<50 copies/mL) were followed-up from the start of 3TC+DTG. The cohort was divided into two groups based on compliance or not with the inclusion criteria of TANGO study (absence of HBV-coinfection, of previous virological failure (VF), of a M184V-harboring virus and of previous AIDS-event other than cutaneous Kaposi’s sarcoma and nadir CD4 count≤200 mm3). Time to VF (i.e. 2 consecutive HIV-RNA determinations ≥50 cps/mL or a single HIV-RNA≥1000 cps/mL) and to treatment discontinuation (TD, i.e. the interruption of any of the study drugs) in the 2 groups were compared through Kaplan-Meier with log-rank test and Cox-regression model after adjusting for the main clinical and demographic between-groups differences. Changes in immunological parameters were assessed by linear mixed model for repeated measures. We analyzed 557 patients with a median follow-up time of 22 months: 145 (26.0%) met the TANGO inclusion criteria (TANGO group, TG).
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaClinical Infectious Diseases
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • dual therapy
  • hiv

Fingerprint Entra nei temi di ricerca di 'Shall we dance? Extending tango's results to clinical practice'. Insieme formano una fingerprint unica.

Cita questo